Nasopharyngeal carcinoma
Conditions
Interventions
Case series:chemotherapy +SBRT+ cetuximab
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged=18; 2. The general situation is good, KPS score > 70 (Appendix I); 3. Nasopharyngeal carcinoma was confirmed by histology or cytology; 4. Patients with oligometastases who had ever received radiotherapy or chemotherapy and achieved disease control (CR, PR or SD), and nonmetastatic patients receiving treatment 5 years later; 5. Appropriate hematological parameters and liver and kidney function: Neutrophil absolute value is more than 1.5 * 10^9/L; The platelet count is over 75 * 10^9/L; Serum total bilirubin is less than 1.5 * upper limit of normal; AST and ALT is less than 2.5 * upper limit of normal (if abnormal liver function is caused by tumor, AST and ALT is less than 5 * upper limit of the normal value); Serum creatinine is less than 1.5 * upper limit of the normal value calculated by Coclcroft-Gault formula creatinine clearance rate greater than 50mL/min; 6. The expected survival time is more than 3 months; 7. Patients must be informed the content of this research and signed the informed consent before treatment.
Exclusion criteria
Exclusion criteria: (1) Hypersensitivity to cetuximab; (2) Losers who had received 1 or more palliative chemotherapy regimens; (3) Peripheral neuropathy is more than CTC grade 2; (4) Neurological or mental abnormalities that affect cognitive ability; (5) Patients with central nervous system metastasis; (6) Uncontrolled accompanying diseases in the first 6 months, including unstable angina pectoris, acute myocardial infarction, cerebrovascular accident, etc; (7) Woman who is pregnant or lactation or having fertility without taking contraceptive measures; (8) The history of other malignant tumors, but the period of disease free survival is not more than 5 years; (9) Combined with other antitumor treatment or other intervention clinical trials at the same time; (10) The patients for the psychological and family living society are not compatible with this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival, OS; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival, PFS; | — |
Countries
China
Contacts
Public ContactYan Li
West China Hospital, Sichuan University
Outcome results
None listed